化合物PD146176 T7530
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
10 mg | 4079-26-9 | ¥2,080.00 | 询底价 |
1 mL | 4079-26-9 | ¥1,220.00 | 询底价 |
25 mg | 4079-26-9 | ¥3,920.00 | 询底价 |
2 mg | 4079-26-9 | ¥797.00 | 询底价 |
5 mg | 4079-26-9 | ¥1,330.00 | 询底价 |
1 mg | 4079-26-9 | ¥546.00 | 询底价 |
100 mg | 4079-26-9 | ¥7,730.00 | 询底价 |
50 mg | 4079-26-9 | ¥5,690.00 | 询底价 |
Product Introduction
Bioactivity
英文名: PD146176
描述: PD146176 (NSC-168807) 是一种 15-脂氧合酶(15-LO)抑制剂,抑制兔网织红细胞 15-LO,Ki 为 197 nM,IC50 为 0.54 μM。 它通过刺激老年三重转基因小鼠的自噬来逆转认知障碍、脑淀粉样变性和 tau 病理学。
体外活性: 15-LO by PD146176, an inhibitor of 15-LO with an IC50 in cells or isolated enzyme of 0.5-0.8 microM, may limit atherosclerotic lesion development through regulation of monocyte-macrophage enrichment.?Rabbits exposed to chronic endothelial denudation of the iliac-femoral artery were meal-fed a 0.25% cholesterol (C), 3% peanut oil (PNO), 3% coconut oil (CNO) diet twice daily with and without 175 mg/kg PD146176 for 12 weeks.?In a second study, atherosclerotic lesions were pre-established in rabbits through chronic endothelial denudation and meal-fed a 0.5% C, 3% PNO, 3% CNO diet for 9 weeks and a 0% C/fat diet for 6 weeks prior to an 8 week administration of PD146176 at 175 mg/kg,?q.d. Plasma total and lipoprotein cholesterol exposure were similar in control and PD146176-treated animals in both studies but PD146176 increased plasma triglyceride exposure 2- to 4-fold.?Plasma PD146176 concentrations ranged from 99 to 214 ng/ml at 2 h post-dose.?In the progression study, the iliac-femoral monocyte-macrophage area was reduced 71%, cross-sectional lesion area was unchanged and cholesteryl ester (CE) content was reduced 63%.?In the regression study, size and macrophage content of iliac-femoral, fibrous plaque-like lesions were decreased 34%, CE content was reduced 19% and gross extent of thoracic aortic lesions were reduced 41%.?PD146176 can limit monocyte macrophage enrichment of atherosclerotic lesions and can attenuate development of fibrofoamy and fibrous plaque lesions in the absence of changes in plasma total or lipoprotein cholesterol concentrations[1].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 25 mg/mL (105.34 mM)
H2O : < 0.1 mg/mL (insoluble)
关键字: inhibit | tau | PD 146176 | brain | triple | NSC-168807 | Autophagy | pathology | amyloidosis | transgenic | reticulocyte | impairment | cognitive | mice | PD-146176 | Inhibitor | cells | IC21 | rabbit | NSC 168807 | Ferroptosis | PD146176
相关产品: Erastin | Ethylenediaminetetraacetic acid trisodium salt | Rosiglitazone maleate | ROS-generating agent 1 | L-BUTHIONINE-(S,R)-SULFOXIMINE | (-)-Epicatechin | L-Glutamic acid monosodium salt | Troglitazone | Linagliptin | Deferoxamine Mesylate
相关库: Cell Cycle Compound Library | Bioactive Compounds Library Max | Ferroptosis Compound Library | Inhibitor Library | Apoptosis Compound Library | Metabolism Compound Library | Autophagy Compound Library | NO PAINS Compound Library | Bioactive Compound Library
化合物PD146176 T7530信息由TargetMol中国为您提供,如您想了解更多关于化合物PD146176 T7530报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途